Adynxx (Adynxx) EPS (Diluted) : $-4.03 (TTM As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx EPS (Diluted)?

Adynxx's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.03.

Adynxx's EPS (Basic) for the three months ended in Sep. 2019 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.03.

Adynxx's EPS without NRI for the three months ended in Sep. 2019 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Adynxx EPS (Diluted) Historical Data

The historical data trend for Adynxx's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx EPS (Diluted) Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EPS (Diluted)

Get a 7-Day Free Trial

-104.40

-67.80

-60.60

-35.94

-10.26

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EPS (Diluted)	Get a 7-Day Free Trial															-0.90	-1.50	-1.02	-1.18	-0.33

Competitive Comparison of Adynxx's EPS (Diluted)

For the Biotechnology subindustry, Adynxx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's PE Ratio distribution charts can be found below:

* The bar in red indicates where Adynxx's PE Ratio falls into.

Adynxx EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Adynxx's Diluted EPS for the fiscal year that ended in Dec. 2018 is calculated as

Diluted EPS (A: Dec. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.417	-	0)	/	0.821
	=	-10.25

Adynxx's Diluted EPS for the quarter that ended in Sep. 2019 is calculated as

Diluted EPS (Q: Sep. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.895	-	0)	/	5.808
	=	-0.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.03

Adynxx (OTCPK:ADYX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Adynxx EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Adynxx's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (Adynxx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Executives

Gregory J. Flesher	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning	officer: CHIEF MEDICAL OFFICER	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102